Evidence for Enhanced Intestinal Absorption of Digoxin by P-Glycoprotein Inhibitors

被引:10
作者
Valizadeh, Hadi [2 ]
Mehtari, Maryam [3 ]
Zakeri-Milani, Parvin [1 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Pharm, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Pharm, Drug Appl Res Ctr, Tabriz, Iran
关键词
Digoxin; Macrolides; Efflux; Intestinal permeability; P-glycoprotein; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; MACROLIDE ANTIBIOTICS; RAT; PERMEABILITY; TRANSPORTER; EXSORPTION;
D O I
10.4314/tjpr.v11i6.10
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the influence of macrolides as P-glycoprotein inhibitors on the level of intestinal absorption of digoxin. Methods: Jejunal segments of anaesthetized rats were cannulated and perfused by digoxin in phosphate buffered saline (PBS) at 37 degrees C in the presence or absence of macrolides (erythromycin and clarithromycin). Samples were obtained from outlet tubing at different time points and digoxin concentration assayed. The effective permeability of the drug was calculated after analyzing the samples using reverse-phase HPLC method. Results: Digoxin effective permeability was in the range of 0.24 +/- 0.02 x 10(-4) to 0.32 +/- 0.06 x 10(-4) cm/sec for the control group. The macrolides significantly (p < 0.05) increased intestinal transport of digoxin, with digoxin in the presence of 150 mu M of each macrolide in the range 0.42 +/- 0.08 x 10(-4) to 0.52 +/- 0.07 x 10(-4) cm/sec. However, no significant difference (p > 0.05) was observed between the effects of the two macrolides. Conclusion: The probable explanation for digoxin-macrolide interaction is inhibition of intestinal P-glycoprotein-mediated efflux of digoxin which leads to increased digoxin intestinal absorption.
引用
收藏
页码:939 / 945
页数:7
相关论文
共 22 条
  • [1] Anwar-Mohamed A O.S., 2012, LJPCP, V1, P1
  • [2] Digoxin-Macrolide drug interaction
    Bizjak, ED
    Mauro, VF
    [J]. ANNALS OF PHARMACOTHERAPY, 1997, 31 (09) : 1077 - 1079
  • [3] CA2+ CHANNEL ANTAGONISTS INHIBIT THE INTESTINAL-ABSORPTION OF DIGOXIN IN THE GUINEA-PIG
    BUDIHNA, MV
    STROJAN, P
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 230 (03) : 301 - 305
  • [4] Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells
    Cavet, ME
    West, M
    Simmons, NL
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) : 1389 - 1396
  • [5] Ernest D. O. D. V. M., 1993, GUIDE CARE USE EXPT
  • [6] Intestinal drug transporter expression and the impact of grapefruit juice in humans
    Glaeser, H.
    Bailey, D. G.
    Dresser, G. K.
    Gregor, J. C.
    Schwarz, U. I.
    McGrath, J. S.
    Jolicoeur, E.
    Lee, W.
    Leake, B. F.
    Tirona, R. G.
    Kim, R. B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) : 362 - 370
  • [7] The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
    Greiner, B
    Eichelbaum, M
    Fritz, P
    Kreichgauer, HP
    Von Richter, O
    Zundler, J
    Kroemer, HK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 147 - 153
  • [8] Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver
    Liu, LC
    Mak, E
    Tirona, RG
    Tan, E
    Novikoff, PM
    Wang, PJ
    Wolkoff, AW
    Pang, KS
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (01) : 433 - 448
  • [9] P-glycoprotein and an unstirred water layer barring digoxin absorption in the vascularly perfused rat small intestine preparation:: Induction studies with pregnenolone-16α-carbonitrile
    Liu, Shanjun
    Tam, Debbie
    Chen, Xianghai
    Pang, K. Sandy
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (09) : 1468 - 1479
  • [10] Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
    Mayer, U
    Wagenaar, E
    Dorobek, B
    Beijnen, JH
    Borst, P
    Schinkel, AH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) : 2430 - 2436